Zymeworks (ZYME) Short Interest Ratio & Short Volume

Short interest is the volume of Zymeworks shares that have been sold short but have not yet been covered or closed out. As of November 30th, traders have sold 9,290,000 shares of ZYME short. Learn More on Zymeworks' current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ZYME shares currently have a short interest ratio of 9.0. Learn More on Zymeworks's short interest ratio.

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Zymeworks: Citadel Advisors LLC, and Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

Zymeworks saw a decline in short interest in the month of November. As of November 30th, there was short interest totaling 9,290,000 shares, a decline of 4.0% from the previous total of 9,680,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Zymeworks: Scholar Rock Holding Co. (22.43%), Akero Therapeutics, Inc. (9.82%), Viking Therapeutics, Inc. (23.97%), Xenon Pharmaceuticals Inc. (5.51%), Catalyst Pharmaceuticals, Inc. (7.34%), Protagonist Therapeutics, Inc. (9.88%), HUTCHMED (China) Limited (0.30%), Immunovant, Inc. (30.49%), Apellis Pharmaceuticals, Inc. (23.14%), MoonLake Immunotherapeutics (12.52%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Occidental Petroleum Co. ($3.93 billion), Suncor Energy Inc. ($3.50 billion), T. Rowe Price Group, Inc. ($2.29 billion), PG&E Co. ($1.73 billion), Coinbase Global, Inc. ($1.71 billion), Etsy, Inc. ($1.65 billion), Paramount Global ($1.54 billion), Lucid Group, Inc. ($1.50 billion), Old Dominion Freight Line, Inc. ($1.46 billion), and DICK'S Sporting Goods, Inc. ($1.41 billion). View all of the most shorted stocks.

Short selling ZYME is an investing strategy that aims to generate trading profit from Zymeworks as its price is falling. ZYME shares are trading up $0.16 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Zymeworks occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of ZYME, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ZYME, twice per month. The most recent reporting period available is November, 30 2022.